Brokerages Set Envista Holdings Co. (NYSE:NVST) PT at $20.21

by · The Cerbat Gem

Shares of Envista Holdings Co. (NYSE:NVST – Get Free Report) have received an average rating of “Hold” from the fourteen analysts that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $20.21.

A number of research analysts recently commented on NVST shares. Robert W. Baird upped their target price on Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Wells Fargo & Company upped their target price on Envista from $20.00 to $21.00 and gave the company an “equal weight” rating in a research note on Thursday, February 6th. Jefferies Financial Group upped their target price on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Leerink Partners upgraded Envista from an “underperform” rating to a “market perform” rating and upped their target price for the company from $16.00 to $23.00 in a research note on Thursday, October 31st. Finally, Leerink Partnrs upgraded Envista from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 31st.

Read Our Latest Analysis on Envista

Envista Stock Down 2.5 %

Shares of NVST stock opened at $20.91 on Tuesday. Envista has a 12 month low of $15.15 and a 12 month high of $23.06. The firm has a market cap of $3.60 billion, a PE ratio of -3.22, a price-to-earnings-growth ratio of 1.27 and a beta of 1.34. The stock has a 50 day moving average of $20.11 and a 200-day moving average of $19.52. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST – Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, equities analysts predict that Envista will post 1 EPS for the current year.

Institutional Trading of Envista

A number of large investors have recently bought and sold shares of the stock. Treasurer of the State of North Carolina grew its holdings in shares of Envista by 0.6% during the fourth quarter. Treasurer of the State of North Carolina now owns 75,560 shares of the company’s stock worth $1,458,000 after purchasing an additional 480 shares during the last quarter. Amalgamated Bank grew its holdings in shares of Envista by 0.7% during the fourth quarter. Amalgamated Bank now owns 80,380 shares of the company’s stock worth $1,551,000 after purchasing an additional 523 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Envista by 30.5% during the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after purchasing an additional 538 shares during the last quarter. M&T Bank Corp grew its holdings in shares of Envista by 4.2% during the fourth quarter. M&T Bank Corp now owns 16,621 shares of the company’s stock worth $320,000 after purchasing an additional 676 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Envista by 50.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after purchasing an additional 728 shares during the last quarter.

Envista Company Profile

(Get Free Report

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.

Featured Stories